CVRx, Inc. announced recently that the Centers for Medicare and Medicaid Services (CMS) assigned the company’s Barostim p ...

Akura Medical, a Shifamed portfolio company focused on venous thromboembolism care, announced recently that the FDA has approve ...

A nationwide retrospective study evaluated health care resource utilization and outcomes among patients with ...

Two-year outcomes were reported from the CLOUT registry, which is a prospective, multicenter study evaluating patient ...

Medtronic and Recor Medical, Inc. (and its parent company, Otsuka Medical Devices Co., Ltd.) separately and independently ...

The 24-month outcomes from the VIVID clinical trial, which evaluated the safety and efficacy of the Duo venous stent system (Ro ...

A study assessed the effects of intravascular volume expansion on deep pelvic vein size using the 200-150-125 rule for the ...

Secondary outcomes through 6 months were reported from the VenaSeal Spectrum Surgical Stripping study, a randomized ...

The Disrupt PAD BTK II study’s 30-day outcomes were revealed. The core lab–adjudicated, prospective, multicenter, s ...

Royal Philips announced enrollment of the first patient in THOR, a United States investigational device exemption (IDE) clinica ...

DEEPER OUS is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland ...

In the LIFE-BTK trial, several initiatives were implemented to facilitate enrollment of diverse populations, ensuring that pati ...